NLM Digital Collections

Search

Start Over Formats Text ✖Remove constraint Formats: Text Subjects Cost-Benefit Analysis ✖Remove constraint Subjects: Cost-Benefit Analysis Subjects Humans ✖Remove constraint Subjects: Humans Copyright Public domain ✖Remove constraint Copyright: Public domain

1. Pharmacogenomics: a primer for policymakers

Publication:
Washington, D.C. : George Washington University, [2008]
Subject(s):
Genetic Testing
Insurance Coverage
Pharmacogenetics -- economics
Pharmacogenetics -- trends
Information Management
Cost-Benefit Analysis
Drug Industry
Health Policy
Health Services Accessibility
Health Services Research
Insurance, Pharmaceutical Services
Pharmaceutical Preparations
Pharmacogenetics -- ethics
Safety
Humans
United States

4. Value-based coverage policy in the United States and the United Kingdom: different paths to a common goal

Publication:
Washington, D.C. : George Washington University, [2006]
Subject(s):
Cost-Benefit Analysis
Evidence-Based Medicine
Insurance Coverage -- economics
Technology Assessment, Biomedical
Formularies as Topic
Medicaid -- economics
Medicare -- economics
Private Sector
State Government
Humans
United Kingdom
United States
United States. Agency for Healthcare Research and Quality.
Blue Cross Association.
Blue Shield Association.
Centers for Medicare & Medicaid Services (U.S.)
National Institute for Health and Clinical Excellence (Great Britain)

5. Factors to consider when making benefit-risk determinations in medical device premarket approval and de novo classifications: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, August 30, 2019
Subject(s):
Cost-Benefit Analysis
Device Approval
Equipment and Supplies -- classification
Equipment Safety -- classification
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

6. Consideration of uncertainty in making benefit-risk determinations in medical device premarket approvals, de novo classifications, and humanitarian device exemptions: guidance for industry and Food and Drug Administration staff

Publication:
Silver Spring, MD : Center for Devices and Radiological Health, August 30, 2019
Subject(s):
Compassionate Use Trials -- standards
Cost-Benefit Analysis
Device Approval -- standards
Equipment and Supplies -- classification
Uncertainty
Data Collection
Reagent Kits, Diagnostic
Research Design
Sample Size
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.